Compare Danaos Corporation (DAC) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaos Corporation vs Quest Diagnostics Inc — how do they compare? Danaos Corporation trades at $138.99 (market cap $2.46B), while Quest Diagnostics Inc trades at $237.51 (market cap $26.21B). The key difference: Quest Diagnostics Inc is far larger — about 10.7× Danaos Corporation's market cap, and Danaos Corporation pays the higher dividend (2.67%). Which is the better fit depends on your goals.
| DAC | DGX | |
|---|---|---|
Market Cap | $2.46B | $26.21B |
Sector | Technology | Health |
52-Week High | $143.15 | $238.50 |
52-Week Low | $84.05 | $173.49 |
Enterprise Value | $2.44B | $31.97B |
Dividend Yield | 2.67% | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DAC trades at $138.94, up 0.45% today, with a bullish technical signal supported by moving averages and oversold RSI indicators. The stock shows strong fundamentals with a low P/E of 4.57, robust net income margin of 51.26%, and consistent earnings beats in recent quarters. Recent news highlights record contracted revenue backlog and dividend declarations, reinforcing positive momentum.
Outlook remains favorable due to undervaluation and earnings strength, but risks include shipping market volatility and capital expenditure pressures. Analyst consensus is split evenly between Buy and Hold, indicating cautious optimism for continued growth amid sector-specific challenges.
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaos Corporation
Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.
Read more on DAC →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
